Clinical Trials Directory

Trials / Completed

CompletedNCT00127153

A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

A Comparative Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of V110 Formulated With Either All New Process Polysaccharides or All Current Process Polysaccharides

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
130 (planned)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
20 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.

Conditions

Interventions

TypeNameDescription
BIOLOGICALV110, pneumococcal vaccine polyvalent

Timeline

Start date
2005-03-01
Primary completion
2005-05-01
Completion
2005-05-01
First posted
2005-08-05
Last updated
2015-01-29

Source: ClinicalTrials.gov record NCT00127153. Inclusion in this directory is not an endorsement.